Patents by Inventor Doris T. Tang
Doris T. Tang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250230168Abstract: Inhibitors of Werner syndrome helicase are provided, including compounds of Formulas J, I, II, III, IIIa, IIIa-1, and IIIa-2, pharmaceutical compositions thereof, and methods of treating cancer.Type: ApplicationFiled: December 20, 2024Publication date: July 17, 2025Inventors: Jason E. ANESINI, Peter A. BLOMGREN, Gediminas J. BRIZGYS, Gregory F. CHIN, Wilian Augusto CORTOPASSI COELHO, Raheel FONDEKAR, Cooper S. JAMIESON, Kerry E. JONES, Andrew V. KELLEGHAN, Scott E. LAZERWITH, Joshua L. MARTIN, Luisruben P. MARTINEZ, Jonathan William MEDLEY, Michael R. MISH, Michael L. MITCHELL, David E. MORTENSON, Sierra C. NGUYEN, Michael S. SANGI, Adam J. SCHRIER, Thomas P. STRATTON, Doris T. TANG, Chandrasekar VENKATARAMANI, William J. WATKINS
-
Publication number: 20250051375Abstract: The invention provides compounds having Formula (I): or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising the same, processes for their preparation, and methods of treating and preventing HIV infection by their administration.Type: ApplicationFiled: May 29, 2024Publication date: February 13, 2025Inventors: Gediminas J. Brizgys, Michael O’ Neil Hanrahan Clarke, Raheel Fondekar, Bindu Goyal, Luisruben P. Martinez, Bradley Thomas Reid, Nathan D. Shapiro, Doris T. Tang
-
Patent number: 12139474Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).Type: GrantFiled: May 24, 2023Date of Patent: November 12, 2024Assignee: Gilead Sciences, Inc.Inventors: Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Kin S. Yang, Anna Zagorska
-
Patent number: 12110294Abstract: The present disclosure provides pyrimidine dione compounds of Formula I and pharmaceutical compositions thereof, for treating cancer, including solid tumors either-used alone or in combination with other anti-cancer agents.Type: GrantFiled: April 29, 2021Date of Patent: October 8, 2024Assignee: Gilead Sciences, Inc.Inventors: Mark J. Bartlett, Gregory F. Chin, Michael O. Clarke, Jennifer L. Cosman, Deeba Ensan, Bindu Goyal, Stephen Ho, Hon C. Hui, Richard L. Mackman, Michael R. Mish, Scott D. Schroeder, Nathan D. Shapiro, Dustin S. Siegel, Doris T. Tang, Hai Yang
-
Patent number: 11999717Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).Type: GrantFiled: December 5, 2022Date of Patent: June 4, 2024Assignee: Gilead Sciences, Inc.Inventors: Brian P. Bestvater, Zhimin Du, Julie Farand, Gregory Notte, Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Peiyuan Wang, Kin S. Yang, Anna Zagorska
-
Patent number: 11912686Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).Type: GrantFiled: December 6, 2022Date of Patent: February 27, 2024Assignee: Gilead Sciences, Inc.Inventors: Brian P. Bestvater, Julie Farand, Doris T. Tang, Kin S. Yang
-
Publication number: 20240043427Abstract: The present disclosure provides pyrimidine dione compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors. The compounds can be used alone or in combination with other anti-cancer agents.Type: ApplicationFiled: April 29, 2021Publication date: February 8, 2024Inventors: Mark J. Bartlett, Gregory F. Chin, Michael O. Clarke, Jennifer L. Cosman, Deeba Ensan, Bindu Goyal, Stephen Ho, Hon C. Hui, Richard L. Mackman, Michael R. Mish, Scott D. Schroeder, Nathan D. Shapiro, Dustin S. Siegel, Doris T. Tang, Hai Yang
-
Publication number: 20240002367Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).Type: ApplicationFiled: May 24, 2023Publication date: January 4, 2024Inventors: Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Kin S. Yang, Anna Zagorska
-
Patent number: 11702407Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non alcoholic steatohepatitis (NASH).Type: GrantFiled: May 13, 2021Date of Patent: July 18, 2023Assignee: Gilead Sciences, Inc.Inventors: Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Kin S. Yang, Anna Zagorska
-
Publication number: 20230212151Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).Type: ApplicationFiled: December 6, 2022Publication date: July 6, 2023Inventors: Brian P. Bestvater, Zhimin Du, Julie Farand, Joshua A. Kaplan, Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Peiyuan Wang, Kin S. Yang, Anna Zagorska
-
Publication number: 20230212149Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).Type: ApplicationFiled: December 5, 2022Publication date: July 6, 2023Inventors: Brian P. Bestvater, Zhimin Du, Julie Farand, Gregory Notte, Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Peiyuan Wang, Kin S. Yang, Anna Zagorska
-
Patent number: 11584738Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).Type: GrantFiled: May 13, 2021Date of Patent: February 21, 2023Assignee: Gilead Sciences, Inc.Inventors: Brian P. Bestvater, Zhimin Du, Julie Farand, Joshua A. Kaplan, Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Peiyuan Wang, Kin S. Yang, Anna Zagorska
-
Publication number: 20230039553Abstract: The present disclosure provides pyrimidine dione compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors. The compounds can be used alone or in combination with other anti-cancer agents.Type: ApplicationFiled: April 29, 2021Publication date: February 9, 2023Inventors: Mark J. Bartlett, Gregory F. Chin, Michael O. Clarke, Jennifer L. Cosman, Deeba Ensan, Bindu Goyal, Stephen Ho, Hon C. Hui, Richard L. Mackman, Michael R. Mish, Scott D. Schroeder, Nathan D. Shapiro, Dustin S. Siegel, Doris T. Tang, Hai Yang
-
Publication number: 20230012262Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).Type: ApplicationFiled: May 13, 2021Publication date: January 12, 2023Inventors: Brian P. Bestvater, Zhimin Du, Julie Farand, Joshua A. Kaplan, Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Peiyuan Wang, Kin S. Yang, Anna Zagorska
-
Patent number: 11548871Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).Type: GrantFiled: November 12, 2020Date of Patent: January 10, 2023Assignee: Gilead Sciences, Inc.Inventors: Brian P. Bestvater, Zhimin Du, Julie Farand, Gregory Notte, Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Peiyuan Wang, Kin S. Yang, Anna Zagorska
-
Publication number: 20210380561Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non alcoholic steatohepatitis (NASH).Type: ApplicationFiled: May 13, 2021Publication date: December 9, 2021Inventors: Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Kin S. Yang, Anna Zagorska
-
Publication number: 20210171500Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).Type: ApplicationFiled: November 12, 2020Publication date: June 10, 2021Inventors: Brian P. Bestvater, Zhimin Du, Julie Farand, Gregory Notte, Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Peiyuan Wang, Kin S. Yang, Anna Zagorska
